title: Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
abstract: OBJECTIVE
  To compare the pharmacokinetics of ceftibuten, cefixime, ceturoxime axetil, and cefaclor after oral administration.
  
  
  METHODS
  Randomized, four-period, crossover study.
  
  
  METHODS
  Hospital-based clinical research center.
  
  
  METHODS
  Healthy adult men and women volunteers.
  
  
  METHODS
  Single 400-mg doses of cefixime and ceftibuten, and 500-mg doses of cefuroxime axetil and cefaclor.
  
  
  RESULTS
  Serum concentrations were determined by high-performance liquid chromatography methods. The mean oral clearances of cefixime, cefuroxime axetil, and cefaclor were similar, ranging from 20.4-27.0 L/hour; clearance of ceftibuten was approximately 4-fold less, 5.45 L/hour. The serum half-lives of ceftibuten (2.35 hrs) and cefixime (2.38 hrs) were prolonged compared with those of cefuroxime axetil (1.30 hrs) and cefaclor (0.693 hr). These agents also differed in terms of time to maximum concentration, time to peak plasma level, area under the curve, and apparent volume of distribution, the last reflecting differences in biovailability.
  
  
  CONCLUSIONS
  Ceftibuten had a relatively high time to maximum concentration and long half-life, resulting in a 3.5-fold higher area under the curve than cefixime, cefuroxime axetil, and cefaclor. These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered.
authors.affiliation: Clinical Pharmacokinetics Laboratory, Millard Fillmore Health System, Buffalo, New York, USA.
authors.forename: D E
authors.initials: DE
authors.lastname: Nix
authors.forename: W T
authors.initials: WT
authors.lastname: Symonds
authors.forename: J M
authors.initials: JM
authors.lastname: Hyatt
authors.forename: J H
authors.initials: JH
authors.lastname: Wilton
authors.forename: M A
authors.initials: MA
authors.lastname: Teal
authors.forename: P
authors.initials: P
authors.lastname: Reidenberg
authors.forename: M B
authors.initials: MB
authors.lastname: Affrime
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D002433:Cefaclor / Q000008:administration & dosage / Q000493:pharmacokinetics*; D020682:Cefixime; D002439:Cefotaxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000077722:Ceftibuten; D002444:Cefuroxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D002511:Cephalosporins; D002433:Cefaclor; D020682:Cefixime; D000077722:Ceftibuten; D002439:Cefotaxime; D002444:Cefuroxime; C040738:cefuroxime axetil